Merrimack Pharmaceuticals Inc. (MACK) Financial Statements (2024 and earlier)

Company Profile

Business Address ONE BROADWAY
CAMBRIDGE, MA 02142
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments, including:18,900,00018,900,00019,000,00019,400,00019,400,00013,100,000
Cash and cash equivalents5,989,0006,083,00010,131,00019,401,00019,439,00013,091,000
Short-term investments12,886,00012,821,0008,837,000   
Other undisclosed cash, cash equivalents, and short-term investments25,000(4,000)32,000(1,000)(39,000)9,000
Other undisclosed current assets284,000394,000442,000228,000428,000528,000
Total current assets:19,184,00019,294,00019,442,00019,628,00019,828,00013,628,000
Noncurrent Assets
Other noncurrent assets4,0005,0006,0007,0008,0009,000
Total noncurrent assets:4,0005,0006,0007,0008,0009,000
TOTAL ASSETS:19,188,00019,299,00019,448,00019,635,00019,836,00013,637,000
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:441,000493,000411,000463,000589,000448,000
Accounts payable74,000111,00080,00089,000188,00067,000
Accrued liabilities130,000144,00094,000137,000139,000119,000
Other undisclosed accounts payable and accrued liabilities237,000238,000237,000237,000262,000262,000
Other undisclosed current liabilities      
Total current liabilities:441,000493,000411,000463,000589,000448,000
Noncurrent Liabilities
Total liabilities:441,000493,000411,000463,000589,000448,000
Equity
Equity, attributable to parent18,747,00018,806,00019,037,00019,172,00019,247,00013,189,000
Common stock1,343,0001,343,0001,343,0001,343,0001,342,0001,334,000
Additional paid in capital566,221,000566,040,000565,992,000565,736,000565,541,000558,999,000
Accumulated deficit(548,817,000)(548,577,000)(548,298,000)(547,907,000)(547,636,000)(547,144,000)
Total equity:18,747,00018,806,00019,037,00019,172,00019,247,00013,189,000
TOTAL LIABILITIES AND EQUITY:19,188,00019,299,00019,448,00019,635,00019,836,00013,637,000

Income Statement (P&L) (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Operating expenses(490,000)(531,000)(569,000)(447,000)(607,000)(504,000)
Operating loss:(490,000)(531,000)(569,000)(447,000)(607,000)(504,000)
Nonoperating income
(Investment Income, Nonoperating)
262,000252,000178,000176,000118,00062,000
Loss from continuing operations before income taxes:(228,000)(279,000)(391,000)(271,000)(489,000)(442,000)
Other undisclosed loss from continuing operations (12,000)   (3,000) 
Loss from continuing operations:(240,000)(279,000)(391,000)(271,000)(492,000)(442,000)
Loss before gain (loss) on sale of properties:(442,000)
Income from discontinued operations      
Net income (loss) available to common stockholders, diluted:(240,000)(279,000)(391,000)(271,000)(492,000)(442,000)

Comprehensive Income (USD)

3/31/2024
Q1
12/31/2023
Q4
9/30/2023
Q3
6/30/2023
Q2
3/31/2023
Q1
12/31/2022
Q4
9/30/2022
Q3
Net income (loss):(240,000)(279,000)(391,000)(271,000)(492,000)(442,000)
Comprehensive income (loss), net of tax, attributable to parent:(240,000)(279,000)(391,000)(271,000)(492,000)(442,000)

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: